BaseLaunch together with KPMG invite you to this online event featuring Synendos Therapeutics. The Basel based company builds on groundbreaking research from its co-founders Dr. Andrea Chicca and Prof. Jürg Gertsch from the University of Bern. In November 2020, the company seeded by BaseLaunch raised 21 million dollar in a series A financing co-lead by Kurma Partners and Sunstone Life Science Ventures.
Synendos develops breakthrough therapies for neuropsychiatric disorders, a field of high unmet medical need. By acting on a novel drug target with its Selective Endocannabinoid Reuptake Inhibitors (SERIs), Synendos aims at restoring the normal functioning of the brain, hence treating anxiety and stress-related disorders. The company advances the preclinical and clinical development of selective endocannabinoid reuptake inhibitors (first-in-class), which are covered by strong IP.
This event will have Dr. Andrea Chicca talking about the story of the company, their plans for the future and their approach to developing therapeutics for neuropsychiatric disorders.
Participation is free, however registration is required before January 27, 2021.